Seeking Alpha

Celgene (CELG -2.5%) has halted a Phase III trial of its Revlimid blood cancer drug following a...

Celgene (CELG -2.5%) has halted a Phase III trial of its Revlimid blood cancer drug following a higher number of deaths among patients who were taking the drug than among those taking a placebo. The study was testing the drug on previously untreated, elderly patients with B-cell chronic lymphocytic leukemia. All other Revlimid trials for chronic lymphocytic leukemia are proceeding. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector